Singapore markets open in 46 minutes

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
49.57+0.90 (+1.85%)
At close: 03:59PM EDT

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
41 61 316 81 11

IndustryDiagnostics & Research
Full-time employees17,154

Key executives

NameTitlePayExercisedYear born
Dr. Pierre-Alain Ruffieux Ph.D.Chief Exec. Officer2.71MN/A1969
Mr. Philippe DeeckeChief Financial OfficerN/AN/A1972
Ms. Maria Soler NunezHead of Group OperationsN/AN/AN/A
Mr. Dirk OehlersVP of Investor RelationsN/AN/AN/A
Mr. Andreas BohrerGroup Gen. Counsel & Company Sec.N/AN/AN/A
Ms. Victoria MorganHead of External CommunicationsN/AN/AN/A
Ms. Jennifer ClancySr. Director of Global MarketingN/AN/AN/A
Dr. Caroline Barth M.D.Chief HR OfficerN/AN/A1972
Ms. Constance WardHead of External CommunicationsN/AN/AN/A
Dr. Sanna FowlerHead of External CommunicationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Corporate governance

Lonza Group AG’s ISS governance QualityScore as of 1 October 2022 is 2. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.